DESTINY-Breast03 Phase 3 Study Results
Time to Definitive Deterioration (TDD)
of QLQ-C30 GHS
Time to definitive deterioration, %
100
80
60
T
60
60
T
40
20
20
T
0
1 2
3
4 5
T
T
CO
6
7
8
00
+ Censor
T-DXd (n = 261)
T-DM1 (n = 263)
Ο
DESTINY-Breast03
Daiichi-Sankyo
Median (95% CI) TDD, months
9.7 (7.3-12.5) HR (95% CI): 0.88 (0.70-1.11)
8.3 (7.0-10.3) P value: 0.2829
HH
+
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Patients at risk:
Time, months
79 66 55 50 34 23 16 15 11 10 10 8
37 32 26 23 21 16 12 9 7 4 3 3 1
7
4 3 20
0
T-DXD 261 232 198 179 175 158 146 136 125 116 101 92
T-DM1 263 237 191 171 162 146 121 102 86 70 64 56
EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; HR, hazard ratio; QLQ-C30, Quality of Life Core 30 questionnaire; TDD,
time to definitive deterioration; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
P values are not adjusted for multiple testing. TDD is defined as a >10-point change from baseline.
ESMO BC 2022 #1630 Oral
43View entire presentation